Investor Relations :: Syros Pharmaceuticals, Inc. (SYRS)
Ir Syros. Company Overview...
Read Ir.syros.com news digest here: view the latest Ir Syros articles and content updates right away or get to their most visited pages. Ir.syros.com is not yet rated by Alexa and its traffic estimate is unavailable. It seems that Ir Syros content is notably popular in USA. We haven’t detected security issues or inappropriate content on Ir.syros.com and thus you can safely use it. Ir.syros.com is hosted with Amazon Technologies Inc. (United States) and its basic language is English.
Content verdict: Safe
Website availability: Live
Language: English
Last check:
-
N/A
Visitors daily -
N/A
Pageviews daily -
N/A
Google PR -
N/A
Alexa rank
Best pages on Ir.syros.com
-
Investor Relations — Syros Pharmaceuticals
Company Overview Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros...
Ir.syros.com news digest
-
5 years
Syros to Present at 30th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside...
-
5 years
Syros Announces Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating...
Dose Selected for Ongoing Expansion Cohorts in Ovarian and Breast Cancers Supported by Tolerability Profile and Early Signs of Clinical Activity
Data Highlighted in Oral Plenary Session at EORTC-NCI-AACR Meeting
Management to Host Conference Call and Webcast at 4:00 PM ET Today... -
5 years
Syros Presents New Preclinical Combination Data on SY-1365 and First Preclinical...
SY-1365 Shows Synergistic Anti-Tumor Activity in Combination with Carboplatin in Preclinical Models of Ovarian Cancer, Supporting Ongoing Investigation of the Combination in Phase 1 Trial of SY-1365
Highly Selective and Potent Oral CDK7 Inhibitors Show Substantial Anti-Tumor Effects in Breast and Ovarian Cancer Models, Supporting Advancement of SY-5609 into IND-Enabling Studies... -
5 years
Syros Announces Presentation of New Preclinical Data on SY-1365 in Treatment-Res...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent...
Domain history
| Web host: | Amazon Technologies Inc. |
| Registrar: | Network Solutions, LLC |
| Registrant: | Syros Pharmaceuticals |
| Updated: | May 21, 2022 |
| Expires: | July 20, 2027 |
| Created: | July 20, 2002 |
Whois record
Safety scores
Trustworthiness
N/AChild safety
N/A
